TIAN Qianqian, WU Qiuchan, FENG Yuanjun, ZHANG Zulong, LI Mei, ZHANG Xuan, XIE Moujin, QING Qunchao, LIU Lei. Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 86-89, 94. DOI: 10.7619/jcmp.20242826
Citation: TIAN Qianqian, WU Qiuchan, FENG Yuanjun, ZHANG Zulong, LI Mei, ZHANG Xuan, XIE Moujin, QING Qunchao, LIU Lei. Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy[J]. Journal of Clinical Medicine in Practice, 2024, 28(18): 86-89, 94. DOI: 10.7619/jcmp.20242826

Impact of Coronavirus Disease 2019 on long-term renal function in patients with chronic kidney disease undergoing no renal replacement therapy

More Information
  • Received Date: July 02, 2024
  • Revised Date: August 28, 2024
  • Objective 

    To investigate the impact of Coronavirus Disease 2019 (COVID-19) on long-term renal function in patients with chronic kidney disease (CKD) who received no renal replacement therapy.

    Methods 

    Thirty-nine CKD patients with an estimated glomerular filtration rate (eGFR) < 60 mL/(min·1.73 m2) at the time of COVID-19 diagnosis, admitted to Guizhou Aerospace Hospital from December 2022 to March 2023, were enrolled in the COVID-19 group. Additionally, 40 CKD patients without COVID-19 from September to December 2021, were included in control group. Changes in eGFR were compared between the two groups, and the temporal trend of eGFR in the COVID-19 group was analyzed using a mixed-effects linear model.

    Results 

    No statistically significant differences were observed in eGFR levels at baseline, 1- and 3-month of follow-up between the COVID-19 and control groups (P>0.05). However, at 1 year of follow-up, the eGFR level in the COVID-19 group was significantly lower than that in the control group (P < 0.05). The mixed-effects linear model analysis revealed a decrease in eGFR by 1.84 mL/(min·1.73 m2) within 1 year of COVID-19 onset in the COVID-19 group, which inclined 4.62% from baseline, with the most significant decline (7.45%) observed among diabetic patients.

    Conclusion 

    Patients with CKD who have not undergone renal replacement therapy experience a substantial decline in eGFR and worsened renal function within 1 year of COVID-19, necessitating close long-term renal function monitoring and timely interventions.

  • [1]
    WIERSINGA W J, RHODES A, CHENG A C, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19): a review[J]. JAMA, 2020, 324(8): 782-793. doi: 10.1001/jama.2020.12839
    [2]
    GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. doi: 10.1056/NEJMoa2002032
    [3]
    OZTURK S, TURGUTALP K, ARICI M, et al. Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey[J]. Nephrol Dial Transplant, 2020, 35(12): 2083-2095. doi: 10.1093/ndt/gfaa271
    [4]
    KANG S H, KIM S W, KIM A Y, et al. Association between chronic kidney disease or acute kidney injury and clinical outcomes in COVID-19 patients[J]. J Korean Med Sci, 2020, 35(50): e434. doi: 10.3346/jkms.2020.35.e434
    [5]
    BOWE B, XIE Y, XU E, et al. Kidney outcomes in long COVID[J]. J Am Soc Nephrol, 2021, 32(11): 2851-2862. doi: 10.1681/ASN.2021060734
    [6]
    CARRIAZO S, MAS-FONTAO S, SEGHERS C, et al. Increased 1-year mortality in haemodialysis patients with COVID-19: a prospective, observational study[J]. Clin Kidney J, 2022, 15(3): 432-441. doi: 10.1093/ckj/sfab248
    [7]
    CHENG Y C, LUO R, WANG K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J]. Kidney Int, 2020, 97(5): 829-838. doi: 10.1016/j.kint.2020.03.005
    [8]
    NUGENT J, AKLILU A, YAMAMOTO Y, et al. Assessment of acute kidney injury and longitudinal kidney function after hospital discharge among patients with and without COVID-19[J]. JAMA Netw Open, 2021, 4(3): e211095. doi: 10.1001/jamanetworkopen.2021.1095
    [9]
    ATIQUZZAMAN M, THOMPSON J R, SHAO S, et al. Long-term effect of COVID-19 infection on kidney function among COVID-19 patients followed in post-COVID-19 recovery clinics in British Columbia, Canada[J]. Nephrol Dial Transplant, 2023, 38(12): 2816-2825. doi: 10.1093/ndt/gfad121
    [10]
    KROLEWSKI A S, NIEWCZAS M A, SKUPIEN J, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria[J]. Diabetes Care, 2014, 37(1): 226-234. doi: 10.2337/dc13-0985
    [11]
    WANNER C, HEERSPINK H J L, ZINMAN B, et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial[J]. J Am Soc Nephrol, 2018, 29(11): 2755-2769. doi: 10.1681/ASN.2018010103
    [12]
    NOJIMA J, MEGURO S, OHKAWA N, et al. One-year eGFR decline rate is a good predictor of prognosis of renal failure in patients with type 2 diabetes[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2017, 93(9): 746-754. doi: 10.2183/pjab.93.046
    [13]
    TANGRI N, STEVENS L A, GRIFFITH J, et al. A predictive model for progression of chronic kidney disease to kidney failure[J]. JAMA, 2011, 305(15): 1553-1559. doi: 10.1001/jama.2011.451
    [14]
    PAN X W, XU D, ZHANG H, et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis[J]. Intensive Care Med, 2020, 46(6): 1114-1116. doi: 10.1007/s00134-020-06026-1
    [15]
    BUONAGURO F M, ASCIERTO P A, MORSE G D, et al. Covid-19: time for a paradigm change[J]. Rev Med Virol, 2020, 30(5): e2134. doi: 10.1002/rmv.2134
    [16]
    HENDERSON L A, CANNA S W, SCHULERT G S, et al. On the alert for cytokine storm: immunopathology in COVID-19[J]. Arthritis Rheumatol, 2020, 72(7): 1059-1063. doi: 10.1002/art.41285
    [17]
    LI H, LIU L, ZHANG D Y, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses[J]. Lancet, 2020, 395(10235): 1517-1520. doi: 10.1016/S0140-6736(20)30920-X
    [18]
    TANG N, BAI H, CHEN X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy[J]. J Thromb Haemost, 2020, 18(5): 1094-1099. doi: 10.1111/jth.14817
    [19]
    TERPOS E, NTANASIS-STATHOPOULOS I, ELALAMY I, et al. Hematological findings and complications of COVID-19[J]. Am J Hematol, 2020, 95(7): 834-847. doi: 10.1002/ajh.25829
    [20]
    JANSEN J, REIMER K C, NAGAI J S, et al. SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids[J]. Cell Stem Cell, 2022, 29(2): 217-231. e8. doi: 10.1016/j.stem.2021.12.010

Catalog

    Article views (83) PDF downloads (6) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return